Rafael Rosell

List of Publications by Year
in descending order

281 papers	35,077 citations	13068 68 h-index	3563 181 g-index
298 all docs	298 docs citations	298 times ranked	28128 citing authors

#	Article	IF	Citations
1	The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC. Lung Cancer, 2022, 164, 8-13.	0.9	3
2	Digital multiplexed analysis of circular RNAs in FFPE and fresh nonâ€small cell lung cancer specimens. Molecular Oncology, 2022, 16, 2367-2383.	2.1	10
3	Promising outlook with sugemalimab in non-small-cell lung cancer. Lancet Oncology, The, 2022, 23, 186-188.	5.1	3
4	Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy. Cancers, 2022, 14, 1574.	1.7	8
5	Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelialâ€“Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells. Pharmaceuticals, 2022, 15, 381.	1.7	6
6	Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. Journal of Clinical Investigation, 2022, 132, .	3.9	15
7	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. Journal of Clinical Oncology, 2022, 40, 3323-3343.	0.8	63
8	Location of EGFR exon 20 insertions matters. Cancer Cell, 2022, 40, 705-708.	7.7	0
9	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. Journal of Clinical Oncology, 2022, 40, 3310-3322.	0.8	60
10	Unmasking the expression of PD-L1 in Myeloid Derived Suppressor Cells: A case study in lung cancer to discover new drugs with specific on-target efficacy. Translational Oncology, 2021, 14, 100969.	1.7	4
11	Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs, 2021, 81, 257-266.	4.9	57
12	Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells. Translational Oncology, 2021, 14, 100887.	1.7	10
13	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2021, 5, 93-102.	1.5	31
14	Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer. Lancet, The, 2021, 397, 557-559.	6.3	4
15	Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform. Clinical Chemistry, 2021, 67, 554-563.	1.5	12
16	A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. Translational Lung Cancer Research, 2021, 10, 1536-1556.	1.3	28
17	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 2021, 39, 1040-1091.	0.8	192
18	BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib. JTO Clinical and Research Reports, 2021, 2, 100113.	0.6	4

#	Article	IF	Citations
19	Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. Lung Cancer, 2021, 154, 113-117.	0.9	5
20	Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation disease. European Journal of Cancer, 2021, 149, 233-234.	1.3	1
21	Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment. Molecular Oncology, 2021, 15, 1667-1682.	2.1	20
22	Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. Lung Cancer, 2021, 155, 183-190.	0.9	8
23	EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP). JCO Precision Oncology, 2021, 5, 839-848.	1.5	3
24	OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs. Cells, 2021, 10, 1148.	1.8	2
25	Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells. Npj Precision Oncology, 2021, 5, 65.	2.3	20
26	Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. Pharmacological Research, 2021, 170, 105701.	3.1	15
27	Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. British Journal of Cancer, 2021, 125, 1602-1611.	2.9	25
28	Clinicopathologic Features and Response to Therapy ofNRG1Fusionâ€“Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	0.8	32
29	First-line osimertinib in patients with epidermal growth factor receptorâ€“mutant nonâ€“small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. European Journal of Cancer, 2021, 159, 174-181.	1.3	5
30	A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Translational Lung Cancer Research, 2021, 10, 4511-4525.	1.3	6
31	KRAS inhibitors, approved. Nature Cancer, 2021, 2, 1254-1256.	5.7	13
32	Mechanisms of resistance to osimertinib. Journal of Thoracic Disease, 2020, 12, 2851-2858.	0.6	62
33	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. Journal of Thoracic Oncology, 2020, 15, 416-425.	0.5	17
34	Immunotherapy at any line of treatment improves survival in patients with advanced metastatic nonâ€small cell lung cancer (NSCLC) compared with chemotherapy (QuijoteCLICaP). Thoracic Cancer, 2020, 11, 353-361.	0.8	36
35	Novel molecular targets for the treatment of lung cancer. Current Opinion in Oncology, 2020, 32, 37-43.	1.1	20
36	Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer, 2020, 150, 62-69.	0.9	15

#	Article	IF	Citations
37	Targeting MET amplification in EGFR-mutant non-small-cell lung cancer. Lancet Respiratory Medicine,the, 2020, 8, 1068-1070.	5.2	11
38	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1810-1821.	1.3	7
39	SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations. IScience, 2020, 23, 101832.	1.9	11
40	Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer. Lancet Oncology, The, 2020, 21, 736-738.	5.1	2
41	Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America. JCO Global Oncology, 2020, 6, 752-760.	0.8	11
42	Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies. Cancers, 2020, 12, 1475.	1.7	69
43	Impact of the APE1 Redox Function Inhibitor E3330 in Non-Small Cell Lung Cancer Cells Exposed to Cisplatin: Increased Cytotoxicity and Impairment of Cell Migration and Invasion. Antioxidants, 2020, 9, 550.	2.2	23
44	Response rate of patients with baseline brain metastases from recently diagnosed nonâ€small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status. Thoracic Cancer, 2020, 11, 1026-1037.	0.8	11
45	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 2020, 38, 1608-1632.	0.8	301
46	Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection. JAMA Oncology, 2020, 6, 1063.	3.4	70
47	Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma. JTO Clinical and Research Reports, 2020, 1, 100084.	0.6	2
48	Characterising acquired resistance to erlotinib in non-small cell lung cancer patients. Expert Review of Respiratory Medicine, 2019, 13, 1019-1028.	1.0	8
49	Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2019, 12, 831-840.	1.3	4
50	Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives . OncoTargets and Therapy, 2019, Volume 12, 4567-4575.	1.0	14
51	Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?. Lancet Oncology, The, 2019, 20, 1617-1618.	5.1	3
52	Targeting PKCÎ¹-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. Cell Communication and Signaling, 2019, 17, 137.	2.7	21
53	Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptorâ€“Mutated Lung Adenocarcinoma. JAMA Oncology, 2019, 5, e192553.	3.4	125
54	BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers, 2019, 11, 1381.	1.7	44

#	Article	IF	Citations
55	Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines. Translational Lung Cancer Research, 2019, 8, 340-351.	1.3	12
56	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. Journal of Thoracic Oncology, 2019, 14, 1266-1276.	0.5	78
57	AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nature Communications, 2019, 10, 1812.	5.8	98
58	Co-mutations in EGFR driven non-small cell lung cancer. EBioMedicine, 2019, 42, 18-19.	2.7	16
59	Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy. EBioMedicine, 2019, 42, 20-21.	2.7	1
60	Cancer Stem Cell Biomarkers in EGFR-Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 167-177.	1.1	37
61	Targeting PKCÎ¹-PAK1 in EGFR-mutation positive non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 667-673.	1.3	11
62	Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). International Journal of Biological Sciences, 2019, 15, 2607-2614.	2.6	19
63	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 304-310.	0.5	10
64	Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC). EBioMedicine, 2019, 39, 207-214.	2.7	38
65	Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma. Annals of Translational Medicine, 2019, 7, 651-651.	0.7	18
66	Adjuvant therapy for resected EGFR -mutant non-small-cell lung cancer. Lancet Oncology, The, 2018, 19, e126.	5.1	3
67	Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2. Cancer Treatment and Research Communications, 2018, 15, 21-31.	0.7	9
68	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876374.	1.4	30
69	Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis. EBioMedicine, 2018, 29, 112-127.	2.7	63
70	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774974.	1.4	200
71	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774501.	1.4	101
72	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 792-800.	0.5	17

#	Article	IF	Citations
73	Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology, 2018, 36, 2244-2250.	0.8	361
74	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. Translational Lung Cancer Research, 2018, 7, 691-702.	1.3	8
75	Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S165-S170.	1.3	14
76	Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. Translational Lung Cancer Research, 2018, 7, S198-S201.	1.3	8
77	A novel miR-205-mediated ERRFI1/EGFR regulatory pathway in MET-addicted cancer cells: emerging biomarkers for secondary resistance. Non-coding RNA Investigation, 2018, 2, 61-61.	0.6	0
78	Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC. Translational Lung Cancer Research, 2018, 7, S183-S186.	1.3	1
79	ARID1A Gene Driver Mutations in Lung Adenocarcinomas. Journal of Thoracic Oncology, 2018, 13, e255-e257.	0.5	24
80	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	0.5	133
81	Avelumab in non-small-cell lung cancer. Lancet Oncology, The, 2018, 19, 1423-1424.	5.1	5
82	Rhomboids and regulation of receptor tyrosine kinase ligands shedding. EBioMedicine, 2018, 37, 19-20.	2.7	2
83	Antiâ€“Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells. Journal of Thoracic Oncology, 2018, 13, 1324-1337.	0.5	29
84	Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer. EBioMedicine, 2018, 33, 16-17.	2.7	4
85	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 1021-1030.	1.1	21
86	Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma. Lancet Respiratory Medicine,the, 2018, 6, 649-651.	5.2	1
87	The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring. Current Oncology Reports, 2018, 20, 70.	1.8	58
88	An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2018, 18, 35-45.	1.5	42
89	Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).. Journal of Clinical Oncology, 2018, 36, 9012-9012.	0.8	7
90	Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. Oncotarget, 2018, 9, 27074-27086.	0.8	8

#	Article	IF	Citations
91	EGFR first- and second-generation TKIsâ€"there is still place for them in EGFR-mutant NSCLC patients. Translational Cancer Research, 2018, 8, S23-S47.	0.4	48
92	Beyond platinum treatment for NSCLC: what does the future hold?. Expert Review of Anticancer Therapy, 2017, 17, 293-295.	1.1	12
93	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. Expert Opinion on Pharmacotherapy, 2017, 18, 295-304.	0.9	12
94	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Nonâ€"Small-Cell Lung Cancer Patients. Clinical Chemistry, 2017, 63, 751-760.	1.5	62
95	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. British Journal of Cancer, 2017, 116, 802-810.	2.9	124
96	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 435-444.	5.2	172
97	Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2017, 26, 713-722.	1.9	17
98	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. Expert Review of Respiratory Medicine, 2017, 11, 469-479.	1.0	11
99	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. Journal of the National Cancer Institute, 2017, 109, .	3.0	196
100	HIP1 expression predicts outcome in breast cancer patients treated with neoadjuvant chemotherapy. Cancer Treatment and Research Communications, 2017, 11, 21-26.	0.7	0
101	P2.06-010 AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study. Journal of Thoracic Oncology, 2017, 12, S1074-S1075.	0.5	1
102	MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results. Journal of Thoracic Oncology, 2017, 12, S379-S380.	0.5	15
103	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Lung Cancer, 2017, 108, 154-160.	0.9	18
104	Using genetics to predict patient response to platinum-based chemotherapy. Expert Review of Precision Medicine and Drug Development, 2017, 2, 21-32.	0.4	7
105	HER3 as a Therapeutic Target in Cancer. BioDrugs, 2017, 31, 63-73.	2.2	29
106	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 1454-1466.	5.1	877
107	Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. Cancer Treatment Reviews, 2017, 60, 1-11.	3.4	29
108	BRAFV600E and BRAF-inactivating mutations in NSCLC. Lancet Oncology, The, 2017, 18, 1286-1287.	5.1	6

#	Article	IF	Citations
109	Brain metastases in patients with EGFR -mutant non-small-cell lung cancer. Lancet Respiratory Medicine,the, 2017, 5, 669-671.	5.2	4
110	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. Journal of the National Cancer Institute, 2017, 109, .	3.0	128
111	Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell, 2017, 32, 238-252.e9.	7.7	235
112	Alectinib versus Crizotinib in Untreated ALK-Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 829-838.	13.9	1,858
113	Immunotherapy for small-cell lung cancer: rationale and clinical evidence. Journal of Xiangya Medicine, 2017, 2, 3-3.	0.2	0
114	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer: Targets and Therapy, 2017, Volume 8, 109-125.	1.3	49
115	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications, 2017, 8, 410.	5.8	117
116	Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Oncotarget, 2017, 8, 47305-47316.	0.8	40
117	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of Clinical Oncology, 2017, 35, 1403-1410.	0.8	277
118	Possible application of circulating free tumor DNA in non-small cell lung cancer patients. Journal of Thoracic Disease, 2017, 9, S1364-S1372.	0.6	13
119	Homage to the titans of Chinese investigation and the race for lung cancer curability. Journal of Thoracic Disease, 2017, 9, S1150-S1150.	0.6	0
120	YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma. Oncotarget, 2017, 8, 48110-48125.	0.8	30
121	Osimertinib: a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma. Translational Cancer Research, 2017, 6, S117-S121.	0.4	1
122	Lung Cancer Pharmacogenomics. , 2017, , 2579-2583.		0
123	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget, 2016, 7, 1066-1075.	0.8	172
124	KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients. Translational Lung Cancer Research, 2016, 5, 511-516.	1.3	20
125	Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report. Translational Lung Cancer Research, 2016, 5, 532-537.	1.3	5
126	Unraveling the genomic complexity of small cell lung cancer. Translational Lung Cancer Research, 2016, 5, 363-366.	1.3	27

#	Article	IF	Citations
127	Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. Translational Lung Cancer Research, 2016, 5, 525-531.	1.3	22
128	Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. OncoTargets and Therapy, 2016, Volume 9, 6361-6376.	1.0	21
129	Liquid Biopsy in Non-Small Cell Lung Cancer. Frontiers in Medicine, 2016, 3, 69.	1.2	48
130	Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. PLoS ONE, 2016, 11, e0154293.	1.1	11
131	Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. BMC Cancer, 2016, 16, 312.	1.1	21
132	P1.42 (also presented as PD2.04): PEM/CBP/BEV Followed by MaintenanceÂPEM/BEV in Hispanic Patients With NSCLC: Outcomes According to TS, ERCC1 and VEGF. Journal of Thoracic Oncology, 2016, 11, S208-S209.	0.5	1
133	Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 3361-3362.	0.8	17
134	RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer. Lancet Oncology, The, 2016, 17, 1623-1625.	5.1	7
135	Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 1683-1696.	5.1	298
136	Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. Pulmonary Therapy, 2016, 2, 1-18.	1.1	2
137	Trends in immunotherapy for brain metastases. Lancet Oncology, The, 2016, 17, 859-860.	5.1	8
138	Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease. Nature Reviews Clinical Oncology, 2016, 13, 401-402.	12.5	35
139	Large-scale screening for somatic mutations in lung cancer. Lancet, The, 2016, 387, 1354-1356.	6.3	111
140	SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 2396-2404.	3.2	103
141	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR -Mutated Population with Advanced NSCLC. Journal of Thoracic Oncology, 2016, 11, 801-807.	0.5	21
142	Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer, 2016, 94, 46-53.	0.9	60
143	Feasibility of cell-free circulating tumor DNA testing for lung cancer. Biomarkers in Medicine, 2016, 10, 417-430.	0.6	21
144	Abstract 336: S49076, a kinase inhibitor of AXL, MET and FGFR with strong, selective preclinical activity against tumor cells with acquired resistance to EGFR inhibitors not carrying the T790M mutation. , 2016, , .		1

#	Article	IF	Citations
145	BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. Oncotarget, 2016, 7, 68933-68942.	0.8	26
146	Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFÎ²2-bioenergetics-mitochondrial priming. Oncotarget, 2016, 7, 82013-82027.	0.8	23
147	Cellular and molecular biology of small cell lung cancer: an overview. Translational Lung Cancer Research, 2016, 5, 2-15.	1.3	52
148	Targeted drugs in small-cell lung cancer. Translational Lung Cancer Research, 2016, 5, 51-70.	1.3	28
149	Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening. EBioMedicine, 2015, 2, 782-783.	2.7	0
150	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Scientific Reports, 2015, 5, 17499.	1.6	55
151	BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Research, 2015, 25, 486-495.	0.6	73
152	Non-small-cell lung cancer. Nature Reviews Disease Primers, 2015, 1, 15009.	18.1	653
153	Evaluation of Biomarkers for HER3-targeted Therapies in Cancer. EBioMedicine, 2015, 2, 192-193.	2.7	3
154	Optimizing lung cancer treatment approaches. Nature Reviews Clinical Oncology, 2015, 12, 75-76.	12.5	59
155	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature Genetics, 2015, 47, 250-256.	9.4	434
156	Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient. Clinical Lung Cancer, 2015, 16, e1-e3.	1.1	8
157	The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials. Oncologist, 2015, 20, 307-315.	1.9	51
158	Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial. Future Oncology, 2015, 11, 421-429.	1.1	9
159	Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Expert Review of Clinical Pharmacology, 2015, 8, 461-477.	1.3	31
160	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 1958-1965.	0.8	280
161	The epidermal growth factor receptor (EGRF) in lung cancer. Translational Respiratory Medicine, 2015, 3, 1.	3.8	34
162	Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors. Future Oncology, 2015, 11, 1259-1274.	1.1	10

#	Article	IF	Citations
163	Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncology, 2015, 1, 149.	3.4	224
164	Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. Expert Review of Respiratory Medicine, 2015, 9, 255-268.	1.0	24
165	Relationship between gene mutation and lung cancer metastasis. Cancer and Metastasis Reviews, 2015, 34, 243-248.	2.7	17
166	AXL Mediates Resistance to PI3KÎ± Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell, 2015, 27, 533-546.	7.7	263
167	Pharmacogenomics in the treatment of lung cancer: an update. Pharmacogenomics, 2015, 16, 1751-1760.	0.6	6
168	The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer. Expert Review of Respiratory Medicine, 2015, 9, 241-244.	1.0	18
169	ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget, 2015, 6, 10577-10585.	0.8	85
170	Platelets and their role in cancer evolution and immune system. Translational Lung Cancer Research, 2015, 4, 713-20.	1.3	15
171	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Translational Lung Cancer Research, 2015, 4, 721-7.	1.3	26
172	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Translational Lung Cancer Research, 2015, 4, 728-42.	1.3	48
173	Cancer stem cells and immunoresistance: clinical implications and solutions. Translational Lung Cancer Research, 2015, 4, 689-703.	1.3	91
174	Real-time liquid biopsies become a reality in cancer treatment. Annals of Translational Medicine, 2015, 3, 36.	0.7	85
175	Melanoma: oncogenic drivers and the immune system. Annals of Translational Medicine, 2015, 3, 265.	0.7	19
176	Other targeted drugs in melanoma. Annals of Translational Medicine, 2015, 3, 266.	0.7	9
177	Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. Cancer Biology and Medicine, 2015, 12, 79-86.	1.4	28
178	Advances in immunotherapy for treatment of lung cancer. Cancer Biology and Medicine, 2015, 12, 209-22.	1.4	50
179	How to Personalize Chemotherapy in Stage IV NSCLC?. , 2015, , 119-129.		2
180	Targeted Therapies for Non-Small Cell Lung Cancer. Current Clinical Pathology, 2015, , 89-101.	0.0	1

#	Article	IF	Citations
181	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. Translational Lung Cancer Research, 2015, 4, 704-12.	1.3	8
182	Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression. Anticancer Research, 2015, 35, 4871-5.	0.5	9
183	Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics. Lung Cancer: Targets and Therapy, 2014, 5, 73.	1.3	3
184	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Expert Review of Anticancer Therapy, 2014, 14, 807-815.	1.1	17
185	TAZIs Highly Expressed in Gastric Signet Ring Cell Carcinoma. BioMed Research International, 2014, 2014, 1-6.	0.9	25
186	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology, 2014, 32, 2780-2787.	0.8	163
187	ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Lancet Respiratory Medicine,the, 2014, 2, 966-968.	5.2	14
188	Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. Journal of Translational Medicine, 2014, 12, 355.	1.8	18
189	Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2014, 20, 4647-4659.	3.2	130
190	Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer, 2014, 83, 211-218.	0.9	64
191	The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research, 2014, 20, 2001-2010.	3.2	215
192	Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. Lung Cancer, 2014, 86, 102-104.	0.9	27
193	What new therapeutic targets exist for EGFR-mutant NSCLC?. Lancet Oncology, The, 2014, 15, 1184-1185.	5.1	3
194	Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Annals of Oncology, 2014, 25, 2147-2155.	0.6	27
195	Treatment of Advanced Nonâ€“Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2014, 15, 173-181.	1.1	56
196	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer, 2014, 84, 161-167.	0.9	81
197	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treatment Reviews, 2014, 40, 990-1004.	3.4	70
198	Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).. Journal of Clinical Oncology, 2014, 32, 8079-8079.	0.8	4

#	Article	IF	Citations
199	ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. Translational Lung Cancer Research, 2014, 3, 122-30.	1.3	25
200	Predicting resistance by selection of signaling pathways. Translational Lung Cancer Research, 2014, 3, 107-15.	1.3	21
201	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Cancer Biology and Medicine, 2014, 11, 173-81.	1.4	20
202	10(th) Congress on Lung Cancer-updates on clinical trials: goal. Translational Lung Cancer Research, 2014, 3, 66-9.	1.3	1
203	A critical question for cancer therapy: what new targets exist?. Translational Lung Cancer Research, 2014, 3, 384-8.	1.3	3
204	Genetics and biomarkers in personalisation of lung cancer treatment. Lancet, The, 2013, 382, 720-731.	6.3	266
205	KRAS Mutations in Lung Cancer. Clinical Lung Cancer, 2013, 14, 205-214.	1.1	182
206	Maintenance therapy and precision medicine in NSCLC. Nature Reviews Clinical Oncology, 2013, 10, 549-550.	12.5	46
207	Mediating Resistance in Oncogene-Driven Cancers. New England Journal of Medicine, 2013, 368, 1551-1552.	13.9	23
208	Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. Future Oncology, 2013, 9, 327-345.	1.1	8
209	Small-cell lung cancer: where are we now and what can we expect for the future?. Future Oncology, 2013, 9, 1065-1068.	1.1	1
210	BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Nonâ€“Small-Cell Lung Cancer Patients with EGFR Mutations. Journal of Thoracic Oncology, 2013, 8, 295-300.	0.5	17
211	Optimal Detection of ALK Rearranged Lung Adenocarcinomas. Journal of Thoracic Oncology, 2013, 8, 255-256.	0.5	19
212	Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).. Journal of Clinical Oncology, 2013, 31, LBA8002-LBA8002.	0.8	2
213	The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget, 2013, 4, 1572-1581.	0.8	23
214	Adaptive resistance to targeted therapies in cancer. Translational Lung Cancer Research, 2013, 2, 152-9.	1.3	36
215	Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2013, 2, 180-8.	1.3	3
216	Comprehensive molecular screening: from the RT-PCR to the RNA-seq. Translational Lung Cancer Research, 2013, 2, 87-91.	1.3	48

#	Article	IF	Citations
217	Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2013, 2, 128-41.	1.3	16
218	Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?. Translational Lung Cancer Research, 2013, 2, 208-21.	1.3	18
219	Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study. Translational Lung Cancer Research, 2013, 2, 58-61.	1.3	1
220	A Genetic Snapshot of Small Cell Lung Cancer. Cancer Discovery, 2012, 2, 769-771.	7.7	16
221	Single Nucleotide Polymorphisms (SNPs) in Non-Small Cell Lung Cancer (NSCLC) Patients. Oncologist, 2012, 17, 1484-1485.	1.9	6
222	Molecular-Based Decision Making for Personalized Cancer Management. , 2012, , .		0
223	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 239-246.	5.1	4,943
224	EGFR mutations in circulating tumour DNA. Lancet Oncology, The, 2012, 13, 971-973.	5.1	28
225	Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells. PLoS ONE, 2012, 7, e41017.	1.1	62
226	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics, 2012, 44, 852-860.	9.4	1,049
227	Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. Pharmacogenomics, 2012, 13, 789-802.	0.6	38
228	First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer, 2011, 72, 84-91.	0.9	37
229	Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer, 2011, 74, 326-331.	0.9	48
230	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. Drugs, 2011, 71, 2231-2246.	4.9	23
231	Predicting Response to Chemotherapy With Early-Stage Lung Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 49-56.	1.0	10
232	FAS and NF-Î¹B signalling modulate dependence of lung cancers on mutant EGFR. Nature, 2011, 471, 523-526.	13.7	374
233	Analysis of the Prognostic Value of Soluble Epidermal Growth Factor Receptor Plasma Concentration in Advanced Nonâ€“Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2011, 12, 320-327.	1.1	15
234	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Review of Respiratory Medicine, 2011, 5, 413-424.	1.0	24

#	Article	IF	Citations
235	mRNA expression levels and genetic status of genes involved in the EGFR and NF-Î²B pathways in metastatic non-small-cell lung cancer patients. Journal of Translational Medicine, 2011, 9, 163.	1.8	24
236	Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Nonâ€“Small-Cell Lung Cancer Patients with EGFR Mutations. Clinical Cancer Research, 2011, 17, 1160-1168.	3.2	292
237	Genome-Wide Association Study of Survival in Nonâ€“Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy. Journal of the National Cancer Institute, 2011, 103, 817-825.	3.0	81
238	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	0.5	4,127
239	Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 286-290.	0.5	75
240	mRNA Expression of BRCA1, PIAS1, and PIAS4 and Survival After Second-line Docetaxel in Advanced Gastric Cancer. Journal of the National Cancer Institute, 2011, 103, 1552-1556.	3.0	53
241	Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 3138-3145.	0.8	351
242	Biomarkers in lung oncology. Pulmonary Pharmacology and Therapeutics, 2010, 23, 508-514.	1.1	11
243	The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer. PLoS ONE, 2010, 5, e9499.	1.1	35
244	XPG mRNA Expression Levels Modulate Prognosis in Resected Nonâ€“Small-Cell Lung Cancer in Conjunction with BRCA1 and ERCC1 Expression. Clinical Lung Cancer, 2009, 10, 47-52.	1.1	61
245	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. New England Journal of Medicine, 2009, 361, 958-967.	13.9	2,213
246	Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression. PLoS ONE, 2009, 4, e5133.	1.1	153
247	Pharmacogenetics in lung cancer for the lay doctor. Targeted Oncology, 2008, 3, 161-171.	1.7	4
248	BRCA1: A New Genomic Marker for Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2008, 9, 331-339.	1.1	44
249	Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2008, 9, S76-S82.	1.1	8
250	PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance. Cancer Investigation, 2008, 26, 1044-1051.	0.6	11
251	Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Journal of Clinical Oncology, 2008, 26, 3552-3559.	0.8	2,119
252	Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. Clinical Cancer Research, 2008, 14, 4794-4799.	3.2	99

#	Article	IF	Citations
253	A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma. Clinical Cancer Research, 2008, 14, 5565-5570.	3.2	77
254	A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells. Journal of Thoracic Oncology, 2008, 3, 1224-1235.	0.5	106
255	Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients. PLoS ONE, 2008, 3, e3695.	1.1	121
256	Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 2747-2754.	0.8	445
257	Cancer and alterations in the endocytic pathway. Future Oncology, 2007, 3, 487-489.	1.1	3
258	Gene Expression and Polymorphisms of DNA Repair Enzymes: Cancer Susceptibility and Response to Chemotherapy. Clinical Lung Cancer, 2007, 8, 369-375.	1.1	28
259	BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer. PLoS ONE, 2007, 2, e1129.	1.1	200
260	Platinum Resistance Related to a Functional NER Pathway. Journal of Thoracic Oncology, 2007, 2, 1063-1066.	0.5	39
261	Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IBâ€“IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncology, The, 2006, 7, 719-727.	5.1	1,458
262	Predicting the outcome of chemotherapy for lung cancer. Current Opinion in Pharmacology, 2006, 6, 323-331.	1.7	68
263	Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Current Opinion in Oncology, 2006, 18, 135-143.	1.1	35
264	DNA Repair by ERCC1 in Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2006, 355, 2590-2591.	13.9	14
265	14-3-3Ïƒ Methylation in Pretreatment Serum Circulating DNA of Cisplatin-Plus-Gemcitabine-Treated Advanced Nonâ€“Small-Cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group. Journal of Clinical Oncology, 2005, 23, 9105-9112.	0.8	114
266	Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas. Clinical Cancer Research, 2005, 11, 5878-5885.	3.2	324
267	Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. Clinical Cancer Research, 2004, 10, 1318-1325.	3.2	345
268	BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics, 2004, 13, 2443-2449.	1.4	291
269	Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery. Clinical Cancer Research, 2004, 10, 4215s-4219s.	3.2	121
270	Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene, 2003, 22, 3548-3553.	2.6	195

#	Article	IF	Citations
271	Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Letters, 2003, 193, 207-216.	3.2	115
272	Nucleotide Excision Repair Pathways Involved in Cisplatin Resistance in Non-Small-Cell Lung Cancer. Cancer Control, 2003, 10, 297-305.	0.7	143
273	Influence of genetic markers on survival in non-small cell lung cancer. Drugs of Today, 2003, 39, 775.	2.4	33
274	O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clinical Cancer Research, 2003, 9, 1461-8.	3.2	111
275	DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer, 2002, 38, 217-227.	0.9	166
276	Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clinical Cancer Research, 2002, 8, 2286-91.	3.2	532
277	Advances in the treatment of non-small cell lung cancer: Molecular markers take the stage. Seminars in Oncology, 2001, 28 Suppl 2, 28-34.	0.8	0
278	A Novel Anti-Apoptosis Gene: Re-expression of Survivin Messenger RNA as a Prognosis Marker in Nonâ€“Small-Cell Lung Cancers. Journal of Clinical Oncology, 1999, 17, 2100-2100.	0.8	475
279	TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene, 1997, 15, 2951-2958.	2.6	45
280	Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall-cell lung cancer: A meta-analytic review. Journal of Surgical Oncology, 1990, 45, 124-130.	0.8	11
281	Defining the landscape of circRNAs in non-small cell lung cancer and their potential as liquid biopsy biomarkers: a complete review including current methods. , 0, , .		2